These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 10717724)

  • 1. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain.
    Zeppetella G
    Palliat Med; 2000 Jan; 14(1):57-8. PubMed ID: 10717724
    [No Abstract]   [Full Text] [Related]  

  • 2. Fentanyl nasal spray (Lazanda) for pain.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):99-100. PubMed ID: 22173454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fentanyl buccal tablet (Fentora) for breakthrough pain.
    Med Lett Drugs Ther; 2007 Sep; 49(1270):78-9. PubMed ID: 17878889
    [No Abstract]   [Full Text] [Related]  

  • 4. Fentanyl intranasal. Breakthrough cancer pain: unsafe packaging.
    Prescrire Int; 2010 Nov; 19(110):251. PubMed ID: 21284356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain.
    Davies A; Sitte T; Elsner F; Reale C; Espinosa J; Brooks D; Fallon M
    J Pain Symptom Manage; 2011 Feb; 41(2):358-66. PubMed ID: 21334555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough pain: progress in management.
    Lossignol DA; Dumitrescu C
    Curr Opin Oncol; 2010 Jul; 22(4):302-6. PubMed ID: 20489619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl pectin nasal spray for breakthrough cancer pain.
    Torres LM; Trinidad JM; Calderón E; Benitez D; Perelman M
    Int J Palliat Nurs; 2015 Mar; 21(3):114-6. PubMed ID: 25815759
    [No Abstract]   [Full Text] [Related]  

  • 9. Fentanyl nasal spray for the treatment of cancer pain.
    Mystakidou K; Panagiotou I; Gouliamos A
    Expert Opin Pharmacother; 2011 Jul; 12(10):1653-9. PubMed ID: 21609189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of intravenous fentanyl against morphine tolerance in breakthrough cancer pain: a case series and literature review.
    Hwang IC; Bruera E; Park SM
    Am J Hosp Palliat Care; 2014 Feb; 31(1):109-11. PubMed ID: 23345613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
    Hata A; Katakami N; Masuda Y; Nanjo S; Otsuka K; Kaji R; Fujita S; Iwamori S; Mifune Y; Orita H; Fukae M; Yamatani T
    Gan To Kagaku Ryoho; 2011 Mar; 38(3):415-8. PubMed ID: 21403444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study.
    Zeppetella G
    Palliat Med; 2001 Jul; 15(4):323-8. PubMed ID: 12054149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WITHDRAWN: Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD004311. PubMed ID: 26275024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies.
    Davies A; Zeppetella G; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M; Buchanan A
    Eur J Pain; 2011 Aug; 15(7):756-63. PubMed ID: 21251860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction with intranasal fentanyl for breakthrough pain.
    Veldhorst-Janssen NM; Fiddelers AA; Zandstra H; Kessels AG; Zandstra H; Marcus MA; Neef C; van der Kuy PH
    J Palliat Med; 2012 Jun; 15(6):631-2. PubMed ID: 22656053
    [No Abstract]   [Full Text] [Related]  

  • 16. Pain recurrence on the third day after application of a transdermal fentanyl patch.
    Konishi H; Ishihara C; Chiba M; Endo Y; Yamaji A
    Pharm World Sci; 2005 Aug; 27(4):353. PubMed ID: 16228637
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
    Rauck R; Reynolds L; Geach J; Bull J; Stearns L; Scherlis M; Parikh N; Dillaha L
    Curr Med Res Opin; 2012 May; 28(5):859-70. PubMed ID: 22480131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated strategies for the successful management of breakthrough cancer pain.
    Dickman A
    Curr Opin Support Palliat Care; 2011 Mar; 5(1):8-14. PubMed ID: 21325998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor pain. Fentanyl TTS: a transdermal system for tumor pain therapy].
    Dtsch Med Wochenschr; 1995 Oct; 120(41 Suppl):1-4. PubMed ID: 9022357
    [No Abstract]   [Full Text] [Related]  

  • 20. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.